Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Biocon Announces Launch of EYLEA® Interchangeable Biosimilar Yesafili™ While PGR ...

15 August 2026 · By · Wire by Fusion42

Published

15 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at jdsupra.com →

◆ Verified

Fusion42 · 15 August 2026 · Fusion42 review

Biocon has launched Yesafili™, an interchangeable biosimilar to EYLEA®, despite a denial of a patent term extension (PGR). This introduces a regulatory approval milestone for interchangeable biosimilars in the pharmaceutical market.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You have a new chance to compete with branded biologics without patent barriers in the US. This clearance changes the path for biosimilar adoption and substitution in ophthalmology drugs.

◆ Coverage

1 source · 15 Aug 2026

◆ Related on Wire

◆ Topics

Biotechbiosimilarpharma-regulationinterchangeable-biosimilarus-marketpatent-denial